Company Encyclopedia
View More
name
Tonix Pharma
TNXP.US
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company’s products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer’s disease, alcohol use disorder, and multi-site pain associated with Long COVID.
1.935 T
TNXP.USMarket value -Rank by Market Cap -/-

Financial Score

27/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking130/401
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-64.99%E
    • Profit Margin-963.38%E
    • Gross Margin58.45%B
  • Growth ScoreC
    • Revenue YoY-8.79%D
    • Net Profit YoY26.64%B
    • Total Assets YoY165.76%A
    • Net Assets YoY211.47%A
  • Cash ScoreD
    • Cash Flow Margin-10.38%D
    • OCF YoY-8.79%D
  • Operating ScoreE
    • Turnover0.06E
  • Debt ScoreA
    • Gearing Ratio8.44%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tonix Pharmaceuticals Holding Corp. releases report on monoclonal antibody TNX-4800 for Lyme disease prevention

    Tonix Pharmaceuticals Holding Corp. has released a report on TNX-4800, a monoclonal antibody for Lyme disease prevention. The document highlights the growing prevalence of Lyme disease and the potential of monoclonal antibodies as a preventive treatment. This AI-generated news brief is for informational purposes only and not financial advice. The original content was published by Tonix Pharmaceuticals on December 24, 2025.

    Reuters·
    US
    TNXP
    -3.13%
    Reuters·
    US
    TNXP
    -3.13%

    Tonix Pharma (TNXP) Receives a Buy from Noble Financial

    Noble Financial's Robert LeBoyer reiterated a Buy rating for Tonix Pharma (TNXP) with a $70 price target. LeBoyer, who covers the Healthcare sector, has an average return of -12.1% and a 27.44% success rate. Alliance Global Partners also issued a Buy rating, while TR | OpenAI reiterated a Hold rating on TNXP.

    Tip Ranks·
    US
    TNXP
    -3.13%
    Tip Ranks·
    US
    TNXP
    -3.13%

    Tonix Pharmaceuticals Licenses TNX-4900 for Neuropathic Pain

    Tonix Pharmaceuticals has licensed exclusive worldwide rights to TNX-4900, a selective Sigma-1 receptor antagonist, for chronic neuropathic pain. This non-opioid treatment has shown efficacy in animal models and aims to address the need for safer pain management. Further studies are planned to support an FDA IND application.

    TradingView·
    US
    TNXP
    -3.13%
    TradingView·
    US
    TNXP
    -3.13%

    Tonix Pharmaceuticals Names Irina Ishak General Counsel

    Tonix Pharmaceuticals Holding Corp. has appointed Irina Ishak as General Counsel, effective December 8, 2025. She will oversee legal, corporate governance, and compliance functions.

    Reuters·
    US
    TNXP
    -3.13%
    Reuters·
    US
    TNXP
    -3.13%

    Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?

    Tonix Pharmaceuticals Holding (NASDAQ:TNXP) has a cash runway of 2.5 years with US$190m in cash and zero debt as of September 2025. However, its cash burn increased by 10% while operating revenue dropped 8.8%. The cash burn is 41% of its US$188m market cap, raising concerns about potential shareholder dilution if new shares are issued. Investors should monitor its cash burn situation closely.

    Simplywall·
    US
    TNXP
    -3.13%
    Simplywall·
    US
    TNXP
    -3.13%
    © 2025 Longbridge｜Disclaimer